neuroendocrine research
Evidence · HighPT-141
Also known as: Bremelanotide
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist (with activity at MC3R and MC4R).
Research context
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist (with activity at MC3R and MC4R). Preclinical studies focus on central melanocortin pathway signaling. The compound is approved as a therapeutic in the U.S. under a different regulatory pathway; the material supplied here is a research-grade reference and is not the approved therapeutic product.
Storage & stability
Store lyophilized at -20°C.
Purity & testing standards
Each batch of PT-141 is analyzed by an independent third-party laboratory. Standard release testing includes reverse-phase HPLC at 220 nm (purity target HPLC ≥99%), electrospray mass spectrometry (identity confirmation), and endotoxin screening. Batch numbers on each vial resolve to a downloadable COA on this site.